Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice.

ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78

The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 7.27

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer (2000) 3.46

ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res (2011) 2.71

Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res (2000) 2.63

Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol (2010) 1.87

Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol (2009) 1.71

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer (2006) 1.67

p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol (1997) 1.67

Clear cell carcinoma of the ovary: a review of the literature. Gynecol Oncol (2012) 1.59

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol (2006) 1.26

Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer (2012) 1.26

Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol (2004) 1.23

Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions. Neoplasia (2012) 1.22

"Mesonephroma" of ovary. Tumor of Müllerian nature related to the endometrioid carcinoma. Cancer (1967) 1.20

Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer (1996) 1.19

Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med (1997) 1.18

Clear cell carcinoma of the ovary: potential pathogenic mechanisms (Review). Oncol Rep (2010) 1.16

Allelotyping of endometriosis with adjacent ovarian carcinoma reveals evidence of a common lineage. Cancer Res (1998) 1.12

Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. Am J Surg Pathol (2011) 1.04

Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A. Int J Gynecol Pathol (2012) 1.02

Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases. Am J Surg Pathol (2008) 0.96

Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27. Histopathology (2002) 0.94

Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer (2006) 0.91

Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites. Int J Gynecol Pathol (2011) 0.91

Endometrioid and clear cell carcinoma of the ovary. Cancer (1972) 0.90

Annexin IV is differentially expressed in clear cell carcinoma of the ovary. Int J Gynecol Cancer (2009) 0.89

Clear cell adenocarcinoma with a component of poorly differentiated histology: a poor prognostic subgroup of ovarian clear cell adenocarcinoma. Int J Gynecol Pathol (2011) 0.85

Prognostic determinants in patients with uterine and ovarian clear carcinoma. Gynecol Oncol (2012) 0.81

Histological spectrum of angiofibroma of soft tissue: histological and genetic analysis of 13 cases. Histopathology (2016) 0.81

Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol. Clin Lung Cancer (2016) 0.77

Nestin is a wide-spectrum abluminal cell marker of salivary gland tumors. Pathol Int (2013) 0.76

CD10 down expression in follicular lymphoma correlates with gastrointestinal lesion involving the stomach and large intestine. Cancer Sci (2016) 0.75

Fatal glioblastoma after Gamma Knife radiosurgery for arteriovenous malformation in a child. J Clin Neurosci (2014) 0.75

Diagnostic value of Thallium-201 scintigraphy in differentiating malignant bone tumors from benign bone lesions. Ann Nucl Med (2015) 0.75

Gastric neuroendocrine tumor arising from heterotopic pancreas. Clin J Gastroenterol (2017) 0.75